<DOC>
	<DOCNO>NCT02319031</DOCNO>
	<brief_summary>The purpose study determine combination Daclatasvir , Sofosbuvir Ribavirin 12 16 week safe effective treatment Genotype 3 Chronic Hepatitis C ( HCV ) patient advanced fibrosis compensate cirrhosis . Patients study may already treat prior HCV may never receive treatment HCV .</brief_summary>
	<brief_title>Safety Efficacy Study Combination Daclatasvir ( 60 mg ) , Sofosbuvir ( 400 mg ) Ribavirin ( Weight-based Dosing ) 12 16 Weeks Subjects With Genotype 3 Chronic HCV Infection With Without Prior Treatment Experience Advanced Fibrosis Compensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Must Genotype 3 Chronic HCV Must advance fibrosis ( F3 ) compensate cirrhosis ( F4 ) HCV RNA Viral load â‰¥ 10,000 IU/mL HCV Treatment naive treatmentexperienced Non Genotype 3 mixed genotype Non advance fibrosis compensate cirrhosis Any prior treatment NS5A inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>